Cohen, R., Bennouna, J., Meurisse, A., Tournigand, C., De La Fouchardière, C., Tougeron, D., . . . André, T. (2020). RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The GERCOR NIPICOL phase II study. J Immunother Cancer.
Chicago Style CitationCohen, Romain, et al. "RECIST and IRECIST Criteria for the Evaluation of Nivolumab Plus Ipilimumab in Patients With Microsatellite Instability-high/mismatch Repair-deficient Metastatic Colorectal Cancer: The GERCOR NIPICOL Phase II Study." J Immunother Cancer 2020.
Cita MLACohen, Romain, et al. "RECIST and IRECIST Criteria for the Evaluation of Nivolumab Plus Ipilimumab in Patients With Microsatellite Instability-high/mismatch Repair-deficient Metastatic Colorectal Cancer: The GERCOR NIPICOL Phase II Study." J Immunother Cancer 2020.